Scoparone inhibits proliferation and invasion of colon cancer cell line HCT116

doi:10.16352/j.issn.1001-6325.2025.11.1429

Abstract

Abstract: Objective To investigate the effects of scoparone (Sco) on proliferation and invasion of colon cancer cell line HCT116, and its effect on the expression of epidermal growth factor receptor (EGFR). Methods 1)HCT116 cells were divided into control group, 50Sco group, 100Sco group and 200Sco group. The cells in control group were incubated with culture medium for 48 hrs. The 50Sco group, 100Sco group and 200Sco group were incubated with 50, 100 and 200 μmol/L scoparone for 48 hrs respectively. 2)HCT116 cells were divided into control group, NC-200Sco group, NC-LV+200Sco group and EGFR-LV+200Sco group. The control group was incubated with normal culture medium for 48 hrs. NC-200Sco group was incubated with 200 μmol/L scoparone for 48 hrs. NC-LV and EGFR-LV were infected into HCT116 cells in NC-LV+200Sco group and EGFR-LV+200Sco group, then incubated with 200 μmol/L scoparone for 48 hrs. Cell proliferation was detected by MTT assay and EdU staining, cell apoptosis was detected by flow cytometry and cell invasion was detected by Transwell assay. EGFR mRNA was detected by RT-qPCR, the level of EGFR, Bcl-2, Bax, matrix metalloproteinase (MMP)-2 and MMP-9 protein was detected by Western blot. Results Compared to the control group, the cell viability, proportion of EdU positive cells and counting number of invasive cells in 50Sco group, 100Sco group and 200Sco group all decreased (P＜0.05). Cell apoptosis rate and Bax protein expression increased (P＜0.05), the protein expression of Bcl-2, MMP-2 and MMP-9 decreased (P＜0.05). mRNA and protein expression of EGFR were decreased (P＜0.05). Compared with NC-200 Sco group and NC-LV+200Sco group, the expression level of mRNA and protein of EGFR in EGFR-LV+200Sco group was increased (P＜0.05). Cell viability, proportion of EdU positive cells and counting number of invasive cells all increased (P＜0.05). The cell apoptosis rate and Bax protein expression level were decreased (P＜0.05). The protein expression of Bcl-2, MMP-2 and MMP-9 was increased(P＜0.05). Conclusions Scoparone has anti-colon cancer cell activity and inhibits proliferation as well as invasion of colon cancer cells through inhibition of EGFR.

Key words: colon cancer, scoparone, epidermal growth factor receptor, proliferation, invasion

CLC Number:

R735.3+5

HAN Wei, PAN Wei, ZHANG Man, GAO Xiangyu, KANG Xinkai, ZHU Zhibo, LIU Ruiting. Scoparone inhibits proliferation and invasion of colon cancer cell line HCT116[J]. Basic & Clinical Medicine, 2025, 45(11): 1429-1437.

References

[1] 冯娜欣, 王鹏, 何明璇, 等. 茯苓酸抑制人结肠癌细胞系HT-29增殖[J]. 基础医学与临床, 2023, 43: 1673-1679.
[2] Kim JK, Kim JY, Kim HJ, et al. Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity[J]. PLoS One, 2013, 8: e80391. doi: 10.1371/journal.pone.0080391.
[3] Wu X, Li X, Li J, et al. Scoparone inhibits breast cancer cell viability through the NF-κB signaling pathway[J]. Exp Ther Med, 2023, 26: 328. doi: 10.3892/etm.2023.12027.
[4] Shen H, Wei Y, Yang Q, et al. Scoparone induces both apoptosis and ferroptosis via multiple mechanisms in non-small-cell lung cancer cells[J]. Toxicol In Vitro, 2023, 91: 105627. doi: 10.1016/j.tiv.2023.105627.
[5] Levantini E, Maroni G, Del Re M, et al. EGFR signaling pathway as therapeutic target in human cancers[J]. Semin Cancer Biol, 2022, 85: 253-275.
[6] Dai S, Liu Y, Liu Z, et al. Cancer-associated fibroblasts mediate resistance to anti-EGFR therapies in cancer[J]. Pharmacol Res, 2024, 206: 107304. doi: 10.1016/j.phrs.2024.107304.
[7] González NS, Marchese PV, Baraibar I, et al. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy[J]. Expert Opin Investig Drugs, 2024, 33: 613-625.
[8] Li Y, Zhang C, Ma X, et al. Identification of the potential mechanism of Radix pueraria in colon cancer based on network pharmacology[J]. Sci Rep, 2022, 12: 3765. doi: 10.1038/s41598-022-07815-y.
[9] Idiiatullina E, Al-Azab M, Walana W, et al. EnDuo, a novel derivative of Endostar, inhibits the migration of colon cancer cells, suppresses matrix metalloproteinase-2/9 expression and impedes AKT/ERK activation[J]. Biomed Pharmacother, 2021, 134: 111136. doi: 10.1016/j.biopha.2020.111136.
[10] Ye M, Liu C, Liu J, et al. Scoparone inhibits the development of hepatocellular carcinoma by modulating the p38 MAPK/Akt/NF-κB signaling in nonalcoholic fatty liver disease mice[J]. Environ Toxicol, 2024, 39: 551-561.
[11] Kohsaka S, Hinohara K, Wang L, et al. Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastoma[J]. Neuro Oncol, 2014, 16: 960-970.
[12] Iijima M, Anai M, Kodama T, et al. Epiregulin-blocking antibody inhibits epiregulin-dependent EGFR signaling[J]. Biochem Biophys Res Commun, 2017, 489: 83-88.
[13] Chen Y, Luo Z, Lin J, et al. Exploring the potential mechanisms of Melilotus officinalis (L.) Pall. in chronic muscle repair patterns using single cell receptor-ligand marker analysis and molecular dynamics simulations[J]. Dis Markers, 2022, 2022: 9082576. doi: 10.1155/2022/9082576.
[14] Alam M, Alam S, Shamsi A, et al. Bax/Bcl-2 cascade is regulated by the EGFR pathway: therapeutic targeting of non-small cell lung cancer[J]. Front Oncol, 2022, 12: 869672. doi: 10.3389/fonc.2022.869672.
[15] Xiao LJ, Lin P, Lin F, et al. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion[J]. Int J Oncol, 2012, 40: 1714-1724.